EA013617B1 - Мутации рецептора эпидермального фактора роста - Google Patents

Мутации рецептора эпидермального фактора роста Download PDF

Info

Publication number
EA013617B1
EA013617B1 EA200701804A EA200701804A EA013617B1 EA 013617 B1 EA013617 B1 EA 013617B1 EA 200701804 A EA200701804 A EA 200701804A EA 200701804 A EA200701804 A EA 200701804A EA 013617 B1 EA013617 B1 EA 013617B1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
mutant
mutation
subject
disease
Prior art date
Application number
EA200701804A
Other languages
English (en)
Russian (ru)
Other versions
EA200701804A1 (ru
Inventor
Дэниель Фримэн
Тодд Хуан
Роберт Рейдински
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200701804A1 publication Critical patent/EA200701804A1/ru
Publication of EA013617B1 publication Critical patent/EA013617B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
EA200701804A 2005-02-24 2006-02-23 Мутации рецептора эпидермального фактора роста EA013617B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65626305P 2005-02-24 2005-02-24
PCT/US2006/006751 WO2006091899A2 (en) 2005-02-24 2006-02-23 Epidermal growth factor receptor mutations

Publications (2)

Publication Number Publication Date
EA200701804A1 EA200701804A1 (ru) 2008-06-30
EA013617B1 true EA013617B1 (ru) 2010-06-30

Family

ID=36579263

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701804A EA013617B1 (ru) 2005-02-24 2006-02-23 Мутации рецептора эпидермального фактора роста

Country Status (15)

Country Link
US (2) US7981605B2 (enExample)
EP (1) EP1851243A2 (enExample)
JP (2) JP2008535477A (enExample)
KR (1) KR20070106029A (enExample)
CN (1) CN101208354A (enExample)
AU (2) AU2006216477A1 (enExample)
BR (1) BRPI0607235A2 (enExample)
CA (1) CA2601936C (enExample)
CR (1) CR9390A (enExample)
EA (1) EA013617B1 (enExample)
IL (1) IL185210A0 (enExample)
MX (1) MX2007009963A (enExample)
NO (1) NO20074826L (enExample)
WO (1) WO2006091899A2 (enExample)
ZA (1) ZA200707379B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого
RU2796334C2 (ru) * 2017-06-07 2023-05-22 Пресиджен, Инк. Экспрессия новых клеточных меток

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706804B (en) * 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
EP1851339B1 (en) 2005-02-11 2016-05-18 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting a drug resistant egfr mutant
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
CA2676244C (en) * 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
MX338151B (es) 2007-03-01 2016-04-05 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
PE20090690A1 (es) * 2007-03-13 2009-06-22 Amgen Inc Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
WO2010007537A1 (en) * 2008-07-17 2010-01-21 Koninklijke Philips Electronics N.V. Nanopore device and a method for nucleic acid analysis
CN102137874B (zh) 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
EP3301446B1 (en) * 2009-02-11 2020-04-15 Caris MPI, Inc. Molecular profiling of tumors
US8623604B2 (en) * 2009-09-09 2014-01-07 Quintiles Transnational Corp. Methods for predicting responsiveness of a cancer cell to an anti-IGFR1 antibody by analysis of mutations in PIK3CA
CN103298934A (zh) * 2010-07-07 2013-09-11 卫材R&D管理有限公司 由正常乳腺上皮细胞生产肿瘤细胞的方法
US20120164641A1 (en) * 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
WO2012154908A2 (en) * 2011-05-10 2012-11-15 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
EP2554551A1 (en) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
EP2943578B1 (en) * 2013-01-14 2019-04-10 National Taiwan University Dnazyme for silencing the expression of egfr
CN103739713B (zh) * 2013-12-10 2016-03-09 吴炯 一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
GB2521355A (en) * 2013-12-17 2015-06-24 Kymab Ltd Human targets I
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CN105779480B (zh) * 2016-03-24 2020-03-20 成都康景生物科技有限公司 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN108047308A (zh) * 2018-02-02 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108047309A (zh) * 2018-02-07 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250268A (zh) * 2018-02-08 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218959A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218960A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108409832A (zh) * 2018-03-07 2018-08-17 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218961A (zh) * 2018-03-19 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440649A (zh) * 2018-05-31 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440650A (zh) * 2018-06-04 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108752424A (zh) * 2018-06-04 2018-11-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440651A (zh) * 2018-06-08 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
AU2019315550B2 (en) * 2018-07-31 2021-07-01 Ascentage Pharma (Suzhou) Co., Ltd. Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
KR102370550B1 (ko) * 2019-01-11 2022-03-08 주식회사 진캐스트 Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
KR102286025B1 (ko) * 2019-01-11 2021-08-05 주식회사 진캐스트 유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법
WO2020145715A1 (ko) * 2019-01-11 2020-07-16 주식회사 진캐스트 Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EP4005593A4 (en) * 2019-07-24 2023-08-16 Sinocelltech Ltd. MULTIVARIABLE DOSING METHOD FOR USE IN THE TREATMENT OF HIGH EGFR EXPRESSION CANCER
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003489A1 (en) * 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
WO2001068711A1 (en) * 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
WO2005027710A2 (en) * 2002-09-11 2005-03-31 Sequenom, Inc. Methods for identifying subjects at risk of melanoma and treatments thereof
PT1733056E (pt) 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
ES2564127T5 (es) 2004-06-04 2020-03-26 Genentech Inc Mutaciones en EGFR
KR20110050567A (ko) * 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
EP1883402A2 (en) * 2005-04-13 2008-02-06 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
EP1913157B2 (en) 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003489A1 (en) * 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
WO2001068711A1 (en) * 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAZDAR A. F. ET AL.: "Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, vol. 10, no. 10, October 2004 (2004-10), pages 481-486, XP004586557, ISSN: 1471-4914, the whole document *
HUANG S-F ET AL.: "High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 24, 15 December 2004 (2004-12-15), pages 8195-8203, XP002369911, ISSN: 1078-0432, the whole document *
MARCHETTI A. ET AL.: "EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 23, no. 4, 1 February 2005 (2005-02-01), pages 857-865, XP002369910, ISSN: 0732-183X, the whole document *
PAO W. ET AL.: "EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 36, 7 September 2004 (2004-09-07), pages 13306-13311, XP002334314, ISSN: 0027-8424, the whole document *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2796334C2 (ru) * 2017-06-07 2023-05-22 Пресиджен, Инк. Экспрессия новых клеточных меток
RU2796334C9 (ru) * 2017-06-07 2023-08-24 Пресиджен, Инк. Экспрессия новых клеточных меток
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого

Also Published As

Publication number Publication date
IL185210A0 (en) 2008-01-06
JP2012149070A (ja) 2012-08-09
KR20070106029A (ko) 2007-10-31
NO20074826L (no) 2007-11-23
US7981605B2 (en) 2011-07-19
AU2006216477A1 (en) 2006-08-31
CN101208354A (zh) 2008-06-25
WO2006091899A2 (en) 2006-08-31
US8546107B2 (en) 2013-10-01
ZA200707379B (en) 2008-10-29
BRPI0607235A2 (pt) 2009-08-25
EA200701804A1 (ru) 2008-06-30
CA2601936A1 (en) 2006-08-31
EP1851243A2 (en) 2007-11-07
JP2008535477A (ja) 2008-09-04
WO2006091899A3 (en) 2007-02-22
US20070048754A1 (en) 2007-03-01
MX2007009963A (es) 2007-09-26
CR9390A (es) 2008-01-02
US20120328620A1 (en) 2012-12-27
AU2010241462A1 (en) 2010-12-16
CA2601936C (en) 2014-06-17

Similar Documents

Publication Publication Date Title
EA013617B1 (ru) Мутации рецептора эпидермального фактора роста
JP5905422B2 (ja) Ｋ‐ｒａｓ変異およびＢ‐ｒａｆ変異ならびに抗ＥＧＦｒ抗体療法
RU2589834C2 (ru) Идентификация, оценка и лечение раковых заболеваний с генетической или приобретенной устойчивостью к ингибиторам alk
JP2010521153A (ja) Ｋ‐ｒａｓ変異および抗ＥＧＦｒ抗体療法
WO2015184061A2 (en) Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response
PT1994410E (pt) Métodos e estojos para detecção precoce de cancro ou de predisposição a este
EP2606358B1 (en) Bard1 isoforms in lung and colorectal cancer and use thereof
US7319010B2 (en) Detection and treatment of cancers of the colon
US6544742B1 (en) Detection of genes regulated by EGF in breast cancer
EP1206487A2 (en) Notch receptor ligands and uses thereof
US20250116658A1 (en) Compositions and methods for in vivo protease profiling by immune cell display
JP2005525125A (ja) Ｌｄｌ受容体関連タンパク質１及び２、並びに骨異常又は軟骨異常の治療
JP2009535033A (ja) Ｃｒｉｐｔｏ−３の検出のための組成物および方法
KR20220088910A (ko) 치료 및 진단 표적으로서의 hla-h, hla-j, hla-l, hla-v 및 hla-y
US20040138161A1 (en) Methods of modulating proliferative conditions
KR102015527B1 (ko) 데스모글레인 3의 유전적 변이 및 이의 용도
JP2005224188A (ja) 骨代謝異常疾患に関連した転写因子に制御される遺伝子の選抜法とその利用
AU2013201896A1 (en) Epidermal growth factor receptor mutations
AU2014206164A1 (en) K-ras mutations and anti-EGFr antibody therapy field

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU